Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced the quotation of 2,206 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects in cancer immunotherapy. The issuance of these securities reflects Imugene’s commitment to expanding its market presence and advancing its research and development efforts, potentially benefiting stakeholders through increased investment opportunities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on developing novel therapies for cancer treatment. The company is known for its innovative approach in creating immunotherapies that aim to activate the immune system to fight cancer cells.
YTD Price Performance: -67.01%
Average Trading Volume: 2,983,825
Technical Sentiment Signal: Sell
Current Market Cap: A$122.8M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.